Physician profile
Scott C Boyken
NPI 1245551878
$16,422.89
in general payments reported to CMS, 2019-2025
53 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 96% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $2,379 · 2021: $1,892 · 2022: $2,199 · 2023: $2,510 · 2024: $2,485 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,798 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,798.28 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,279.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,701.12 | 2019-2025 | |
| Lilly USA, LLC | $1,351.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,221.55 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $1,220.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,152.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,079.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $755.59 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $618.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.70 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $309.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $256.04 | 2019-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $227.01 | 2019-2022 | |
| Allergan, INC. | $220.06 | 2019-2020 | |
| Corium, LLC | $206.24 | 2023-2025 | Azstarys |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Boyken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.